Latest Pharmaceutical companies Stories
BRIDGEWATER, New Jersey, April 22, 2013 /PRNewswire/ -- Aurigene and Endo entered into collaboration in 2009, for multiple integrated drug discovery programs in the areas of Inflammation and Oncology. (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) In one of the programs, a novel selective dual kinase inhibitor, targeting both the antigen receptor signalling and cytokine signalling pathways involved in immune regulation for inflammatory disorders,...
HOERSHOLM, Denmark and SAN DIEGO, April 18, 2013 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the EPO has issued Minutes of the Oral Proceedings specifying the Board of Appeal's decision to maintain EP 1015469, the "Wengel" patent, with the claims to amino- and thio-LNA nucleotides and oligonucleotides. (Logo: http://photos.prnewswire.com/prnh/20100111/SPLOGO)...
BRIDGEWATER, New Jersey, April 18, 2013 /PRNewswire/ -- Aurigene has had a number of collaboration programs with large pharma companies over the years, and has reported successes in these programs. (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) Elaborating on the successful collaboration programs, Aurigene's CEO CSN Murthy said "Aurigene combines its excellent execution of integrated drug discovery programs with the deep biological insights and...
PARSIPPANY, N.J., April 3, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States District Court for the District of New Jersey has granted a motion by AstraZeneca seeking a temporary restraining order (TRO) to prevent Actavis from further distribution of its generic version of AstraZeneca's Pulmicort RESPULES(®) (budesonide inhalation suspension) 0.25, 0.5 mg products. Actavis' sales of generic Pulmicort RESPULES(®) have been enjoined until April 12,...
PARSIPPANY, N.J., Jan. 31, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States District Court for the District of Delaware has found United States Patent No. 5,100,899 (the '899 Patent) valid and infringed by Actavis' generic version of Pfizer Inc.'s Rapamune® (sirolimus). The Company said that it was reviewing the court's decision and would evaluate all available options, including an appeal. Rapamune® tablets are indicated for the prophylaxis...
WOODCLIFF LAKE, N.J., Oct. 15, 2012 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has entered into agreements with Watson Pharmaceuticals, Inc. (NYSE: WPI) and Actavis Group to purchase for cash five generic products that are currently marketed in the U.S. by Watson or Actavis, eight Abbreviated New Drug Applications currently awaiting regulatory approval and a generic product in late-stage development. The closing of the purchase agreements is...
NEW YORK and PITTSBURGH, Aug. 22, 2012 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Mylan Inc. (Nasdaq: MYL) today announced that they have signed a definitive agreement to establish an exclusive long-term strategic collaboration to develop, manufacture, distribute and market generic drugs in Japan. The collaboration is designed to build upon each company's highly complementary strengths and quality assets. Under the terms of the agreement, Pfizer's responsibilities primarily...
FARMINGTON, Conn., Aug. 22, 2012 /PRNewswire-iReach/ -- It's a well known data point that while the pills a doctor prescribes may cost pennies each to manufacture, the first pill cost many millions of dollars to research, develop, test, and certify. Along the way, many routes are pursued and ultimately dropped when they fail to yield marketable results. One way drug manufacturers can lower their costs and increase their output is to outsource stages of the process to Contract...
SAN ANTONIO, Texas, Aug. 22, 2012 /PRNewswire/ -- Mission Pharmacal today announced its plans to aggressively market its LYCELLE®( )kit, a safe and highly effective treatment for head lice, just in time for the back-to-school rush. For anxious parents nationwide, the timing couldn't be better since it's the time of year that lice infestations are most rampant. The U.S. Food and Drug Administration (FDA) recently cleared the LYCELLE Head Lice Removal kit for sale as a medical...
PRINCETON, New Jersey, August 22, 2012 /PRNewswire/ -- Med Ad News, PharmaLive and Pharmalot announce the Pharma Interactive Conference on November 7-8, 2012 in Princeton, NJ. The unique and comprehensive two-day program has been specifically designed to provide a solid foundation for an actionable digital sales and marketing strategy for pharmaceutical and biotechnology companies. Expert marketers from pharma industry frontrunners and renowned healthcare marketing agencies...
